Last reviewed · How we verify

Congenital hypoplastic anemia — Treatment Landscape & Competitive Intelligence

Congenital hypoplastic anemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Congenital hypoplastic anemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Anadrol-50 OXYMETHOLONE Pharmobedient oxymetholone Androgen receptor 1972-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortisol Cortisol University of Zurich Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
prednison prednison Wen Zhang Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
prednisolon prednisolon Hannover Medical School Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Congenital hypoplastic anemia
  2. Generic (originally Schering) · 2 drugs in Congenital hypoplastic anemia
  3. Generic (originally Merck/Upjohn) · 1 drug in Congenital hypoplastic anemia
  4. Generic (originally Upjohn/Pfizer) · 1 drug in Congenital hypoplastic anemia
  5. Hannover Medical School · 1 drug in Congenital hypoplastic anemia
  6. Leiden University Medical Center · 1 drug in Congenital hypoplastic anemia
  7. Pfizer · 1 drug in Congenital hypoplastic anemia
  8. Pharmobedient · 1 drug in Congenital hypoplastic anemia
  9. University of Zurich · 1 drug in Congenital hypoplastic anemia
  10. Wen Zhang · 1 drug in Congenital hypoplastic anemia
  11. Generic (originally Merck) · 1 drug in Congenital hypoplastic anemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital hypoplastic anemia:

Cite this brief

Drug Landscape (2026). Congenital hypoplastic anemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-hypoplastic-anemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing